EMA Authorised: Ratiograstim (filgrastim) — Ratiopharm GmbH

View source ↗

Summary

EMA authorised Ratiograstim (filgrastim) by Ratiopharm GmbH for cancer and hematopoietic stem cell transplantation to reduce chemotherapy-induced neutropenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neutropenia

Drugs mentioned

• Ratiograstim (filgrastim)

Snippet

Status: Authorised. Therapeutic area: Hematopoietic Stem Cell Transplantation;Cancer. MAH: Ratiopharm GmbH. Decision date: 21/08/2024